Agent Capital, LLC
Emerging managerSEC exempt reporting adviser (venture capital exemption).
- Website
- HTTPS://WWW.AGENTCAPITAL.COM
- HQ
- MA
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs. Its team includes R. John Glasspool as Venture Partner, Julie Gionfriddo as Head of Investor Relations and Fundraising, and finance and controller staff. Portfolio company Affini-T is developing therapies that orchestrate the immune system to target oncogenic driver mutations.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Seed, Series A, Growth | Not enough dated deals | Series B, Growth, Series A |
| Sectors | Biotech | Not enough dated deals | Biotech, Healthtech, Life sciences and research tools, Medical devices |
| Regions | Not stated | Not enough dated deals | CA, MA, PA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2017 | 2 | Biotech, Healthtech, Medical devices |
| 2018 | 7 | Biotech, Healthtech, Life sciences and research tools |
| 2019 | 2 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 3 | Biotech, Healthtech, HR and future of work |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2017 | 0 | 0 | 0 | 2 | 0 |
| 2018 | 0 | 0 | 3 | 2 | 1 |
| 2019 | 0 | 0 | 1 | 1 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 3 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 1 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Agent Capital Fund III LP Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics that address unmet patient needs. It invests across all stages, from preclinical to commercial, with a focus on rare diseases, oncology, neurology and immunology. Inferred from the firm's website | 2024 | $53.25M to $100M (Form D) | Open, writing first checks |
| Agent Capital Fund II, LP | 2021 | $59.55M to $100M (Form D) | Follow-ons only |
03 · People across funds
- Geeta Vemuri, Managing Member of the General Partner and Managing Partner of the Management Company
Agent Capital Fund III LP (Named on Form D); Agent Capital Fund II, LP (Named on Form D)
- Julie Gionfriddo, Head of Investor Relations and Fundraising
Agent Capital Fund III LP (Team); Agent Capital Fund II, LP (Team)
- Lisa Kraeutler, VP of Fund Finance
Agent Capital Fund III LP (Team); Agent Capital Fund II, LP (Team)
- Lori Forrest, CPA, Controller
Agent Capital Fund III LP (Team); Agent Capital Fund II, LP (Team)
- Marla McMillan, MBA, VP of Fund Finance
Agent Capital Fund III LP (Team); Agent Capital Fund II, LP (Team)
- R. John Glasspool, Venture Partner
Agent Capital Fund III LP (Team); Agent Capital Fund II, LP (Team)
- Bruce A. Peacock, CPA, Operating Partner
On the team page, not linked to a fund
- John Glasspool, Venture Partner
On the team page, not linked to a fund
- Venkata Aditya Kalaga, MTM, Investment Analyst
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- HTTPS://WWW.AGENTCAPITAL.COM
- https://www.agentcapital.com/contact/
- https://www.agentcapital.com/about/
- https://www.agentcapital.com/portfolio/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026